We show that the crosstalk between conventional type I dendritic cells (cDC1) and T cells is essential for an effective aPD-1-mediated anti-tumor response. Accordingly, we developed a bispecific DC-T cell engager (BiCE), a reagent that facilitates physical interactions between PD-1+ T cells ...
A bispecific T cell engager is provided. More specifically, the present invention is directed to bispecific molecules that bind DLL3, MUC17 or CLD18 and activate CD (group of differentiation) molecules (eg, CD3, CD28 and CD137). Also provided are methods of treating diseases such as cancer ...
Furthermore, AMG160, a different type of TRAB known as a bispecific T-cell engager (BiTE) that targets PSMA, showed promising efficacy in patients with metastatic castration-resistant prostate cancer8, and TNB 585, another PSMA-targeted TRAB9, is also in phase I trials. TRAB recognises a ...
et al. Bispecific T cell engager (BiTE(R)) antibody constructs can mediate bystander tumor cell killing. PLOS ONE 12, e0183390 (2017). PubMed PubMed Central Google Scholar Kebenko, M. et al. A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T cell...
Einsele, H. et al. The BiTE (bispecific T-cell engager) platform: development and future potential of a targeted immuno-oncology therapy across tumor types.Cancer126, 3192–3201 (2020). ArticleCASPubMedGoogle Scholar Suurs, F. V., Lub-de Hooge, M. N., de Vries, E. G. E. & de ...
penicillin/streptomycin. All cell lines were maintained at 37 °C in a 5% CO2atmosphere. Construction of αB7-H3-αCD3 bispecific T-cell engager The bispecific T-cell engager (BITE) construct αB7-H3-αCD3, targeting B7-H3 and CD3, was designed to incorporate a signal peptide followed by ...
Bispecific T-cell engaging (BITE) antibodies also encounter clinical challenges, including short half-lives requiring continuous infusion and potential toxicities. Methods To address these issues, we developed a lentiviral system to engineer T cells that secrete αB7-H3-αCD3 bispecific engager ...
ArticleA bispecific T cell engager recruits both type 1 NKT and Vγ9Vδ2-T cells for the treatment of CD1d-expressing hematological malignancies Author links open overlay panelRoeland Lameris 1, Jurjen M. Ruben 2, Victoria Iglesias-Guimarais 2, Milon de Jong 1, Myrthe Veth 1, Fleur S. ...
A long acting modified T-cell engager bispecific antibody with cytokine caps that provides reduced toxicity and boosted anti-tumor activity is disclosed. Method of making the modified and cytokine capped Bi-specific T-cell engager antibody is also disclosed.LIU, SHUMIN...
et al. The BiTE (bispecific T-cell engager) platform: development and future potential of a targeted immuno-oncology therapy across tumor types. Cancer 126, 3192–3201 (2020). Article CAS PubMed Google Scholar Suurs, F. V., Lub-de Hooge, M. N., de Vries, E. G. E. & de Groot...